Psoriatic arthritis: Treatment strategies using anti-inflammatory drugs and classical DMARDs

Reumatismo

Volumn 64, Issue 2, 2012, Pages 107-112

  Lubrano, E ^a   Scarpa, R ^b  

^a UNIVERSITY OF MOLISE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Biomarkers; Joint damage; Psoriatic arthritis

Indexed keywords

AURANOFIN; AZAPROPAZONE; CYCLOSPORIN A; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETRETINATE; IBUPROFEN; INDOMETACIN; INTERLEUKIN 2; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; THIOMALATE SODIUM;

CYTOKINE PRODUCTION; DACTYLITIS; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTHESITIS; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HUMAN; LIVER FUNCTION TEST; LONG TERM SURVIVAL; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NEPHROTOXICITY; PROTEIN EXPRESSION; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN DISEASE; SYNOVITIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84862493540     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: 10.4081/reumatismo.2012.107     Document Type: Review

References (32)

1. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973; 3: 55-78.
2. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990; 17: 809-812.
3. Helliwell PS, Hickling P, Wright V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? Annals of the Rheumatic Diseases 1998; 57:135-140.
4. Pipitone N, Kingsley GH, Manzo A, Scott DL, Pitzalis C. Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology (Oxford). 2003; 42: 1138-1148.
5. Salvarani C, Pipitone N, Marchesoni A, Cantini F, Cauli A, Lubrano E, et al. Recommendation for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol. 2011; 29 (Suppl. 66): S28-S41.
6. Lassuss A. A comparative pilot study of az-apropazone and indomethacin in the treatment of psoriatic arthritis and Reiter's disease. Curr Med Res Opin. 1976; 4: 65-69.
7. Leatham PA, Bird HA, Wright V, Fowler PD. The run-in period in trail design: a comparison of two non-steroidal anti-inflammatory agents in psoriatic arthropathy. Agents Actions. 1982; 12: 221-224.
8. Hopkins R, Bird HA, Jones J, Surrall K, Ast-bury C, et al. A double-blind controlled trial of etetrinate (tigason) and ibuprofen in psoriatic arthritis. Ann Rheum Dis. 1985; 44: 189-193.
9. Wanders A, van Der Heijde D, Landewe R, Behier J, Calin A, Olivieri I, et al. Nonster-oidal antiinflammatory drugs reduce radio-graphic progression in patients with Ankylos-ing Spondylitis. A randomised clinical trial. Arthritis Rheum. 2005; 52: 1756-1765.
10. Griffiths CEM. Therapy for psoriatic arthritis: sometimes a conflict for psoriasis. Br J Der-matol. 1997; 36: 409-412.
11. Soriano E, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. J Rheu-matol. 2006; 33: 1422-1430.
12. Helliwell PS, Taylor WJ. Treatment of pso-riatic arthritis and rheumatoid arthritis with disease modyfing drugs- comparison of drugs and adverse reaction. J Rheumatol. 2008; 35: 472-476.
13. Scarpa R, Peluso R, Atteno M, Manguso F, Spanò A, Iervolin S, et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatology. 2008; 27: 823-826.
14. Ricci M, De Marco G, Desiati F, Mazzocchi L, Rotunno L, Battafarano N, Marchesoni A. So-pravvivenza a lungo termine del trattamento con methotrexate nell'artrite psoriasica. Reu-matismo. 2009; 61: 125-131.
15. Black RL, et al. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA. 1964; 189: 743-747.
16. Willkens RF, William HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984; 27: 376-381.
17. Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A. Comparison of cyclo-sporin A and methotrexate in the treatment of psoriatic arthritis. A one year prospective study. Clin Exp Rheum. 1995; 13: 589-593.
18. Fraser AD, van Kuijk AWR, Westhovens R, Karim Z, Wakefield R, Gerards AH, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005; 64. 859-864.
19. Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Bacon P. Sulphasalazine in psoriatic arthritis: a double-blinde-placebo-controlled study. Br J Rheumatol. 1990; 29: 46-49.
20. Fraser SM, Hopkins R, Hunter JA, Neumann V, Capell HA, Bird HA. Sulphasalazine in the management of psoriatic arthritis. Br J Rheu-matol. 1993; 32: 923-925.
21. Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, et al. Sulphasalazine therapy for psoriatic arthritis: a double blind placebo controlled trial. J Rheumatol. 1995; 22: 894-898.
22. Combe B, Goupille P, Kunts JL, Tebib J, Li-ote F, Bregeon C. Sulphasalazine in psoriatic arthritis: a randomized multi centre, placebo controlled study. Br J Rheumatol. 1996; 35: 664-668.
23. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weismann MH, Taylor T, et al. Comparison of sulphasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996; 39: 2013-2020.
24. Clegg DO, Reda DJ, Adbellatif M. Comparison of sulphasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondy-loarthritis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum, 1999; 42: 2325-2329.
25. Clegg DO, Reda DJ, Weismann MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulphasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996; 39: 2004-2012.
26. Finzi AF, Mozzanica N, Cattaneo A, Chiappi-no A, Chiappino G, Pigatto PD. Effectiveness of cyclopsorine treatment in severe psoriasis: a clinical and immunological study. J Am Acad Dermatol. 1989; 21: 91-97.
27. Salvarani C, Macchioni P, Olivieri I, Mar-chesoni A, Cutolo M, Ferraccioli G, et al. A comparison of cyclosporine, sulphasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol. 2001; 28: 2274-2282.
28. Sarzi-Puttini P, Cazzola M, Panni B, et al. Long-term dafety and efficacy of low-dose cyclkosporin A in severe psoriatic arthritis. Rheumatol Int. 2002; 21: 234-238.
29. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens T, Jones T, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis:a multinational, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2004; 50: 1939-1950.
30. Ravindran V, Scott DL, Choy EH. A systematic review and metaanalysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis. 2008; 67: 855-859.
31. Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol. 1999; 455: 221-225.
32. Grundmann-Kollmann M, Mooser G, Schrad-er P, Zollner T, et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenalate mofetil. J Am Acad Der-matol. 2000; 42: 835-837.